title: Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults.
abstract: In a Phase 1 study, 15 healthy subjects were randomized to receive a 13-valent pneumococcal conjugate vaccine (PCV13) and 15 to receive a 23-valent pneumococcal polysaccharide vaccine (23vPS). Antibody responses were measured immediately before and approximately one month after vaccination. Serotype-specific antibodies were measured using an enzyme-linked immunosorbent assay (ELISA) for immunoglobulin G (IgG) and an opsonophagocytic assay (OPA) for functional antibodies. PCV13 was as immunogenic or more immunogenic than 23vPS and was well tolerated.
authors.affiliation: Wyeth Vaccines Research, 401 N. Middletown Road, Pearl River, NY 10965, USA.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Scott
authors.forename: Steven F
authors.initials: SF
authors.lastname: Komjathy
authors.forename: Branda T
authors.initials: BT
authors.lastname: Hu
authors.forename: Sherryl
authors.initials: S
authors.lastname: Baker
authors.forename: Lois A
authors.initials: LA
authors.lastname: Supan
authors.forename: Carol A
authors.initials: CA
authors.lastname: Monahan
authors.forename: William
authors.initials: W
authors.lastname: Gruber
authors.forename: George R
authors.initials: GR
authors.lastname: Siber
authors.forename: Stephen P
authors.initials: SP
authors.lastname: Lockhart
mesh_terms: D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D006262:Health; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000276:immunology*; D022242:Pneumococcal Vaccines / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines